Doxorubicin versus Idarubicin in Acute Myeloid Leukemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202309818279236

Enrollment

244

Registered

2023-09-01

Start date

2017-09-24

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Haematological Disorders

Interventions

Doxorubicin

Idarubicin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 18 years or older Confirmed AML diagnosis

Exclusion criteria

Exclusion criteria: Patients with current active second malignancy AML M3 (Promyelocytic leukemia) Patients with heart problems (low ejection fraction)

Design outcomes

Primary

Measure	Time frame
Response to treatment;Safety of treatment	—

Secondary

Measure	Time frame
Pharmacoeconomic analysis	—

Countries

Egypt

Contacts

Public ContactMaggie Abbassie

Faculty of Pharmacy

maggie.abbassi@pharma.cu.edu.eg01001589925

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026